Chronic insomnia affects roughly 10 to 15 percent of adults, and for many the first response from a clinician is a prescription. Yet the strongest body of evidence points to a non-drug program as the treatment that actually holds up over months and years.
That program is cognitive behavioral therapy for insomnia, or CBT-I. A 2026 systematic evidence summary in Frontiers in Psychiatry pulled together 28 clinical guidelines, expert consensus statements, systematic reviews and meta-analyses published between 2005 and 2025 and concluded that multicomponent CBT-I is the first-line treatment for chronic insomnia, with minimal adverse effects compared with sleep drugs.
The 2026 review echoes a position major US bodies took years ago. In 2016, the American College of Physicians recommended that all adult patients receive CBT-I as the initial treatment for chronic insomnia disorder, with drugs added only through shared decision-making if therapy alone falls short.
What the six-week program actually involves
CBT-I is not a single technique but a package delivered over roughly four to eight sessions across six to eight weeks. The Frontiers review sets out the core ingredients: stimulus control, which retrains the bed-sleep association, sleep restriction therapy, which tightens time in bed to consolidate sleep, cognitive therapy to defuse the anxious loop of thoughts about not sleeping, relaxation training, and sleep hygiene education. Phototherapy and exercise can be layered in as adjuncts.
Also read: Short, intense workouts may deliver as much heart benefit as long steady ones
Sleep hygiene, the advice most people have already heard about screens, caffeine and bedtime routines, is not enough on its own. The review is explicit that single components underperform, and that "multicomponent CBT-I is consistently more effective than any single-component approach used in isolation."
A separate narrative review in the Journal of General Internal Medicine reports that 70 to 80 percent of patients who complete CBT-I experience significant improvements in sleep.
Why pills fade and therapy sticks
Sleep medications work, but the benefit tends to erode. The 2026 evidence summary notes that pharmacological interventions carry "risks of tolerance, dependence, and adverse effects such as falls, delirium, and daytime somnolence, particularly with long-term use," and that CBT-I "provides better long-term value and sustained benefits beyond treatment cessation compared to medication alone."
The ACP guideline framed the same tradeoff bluntly. "Medications should ideally be used for no longer than four to five weeks while the skills learned in CBT-I can manage insomnia over the longer term," said Wayne J. Riley, then president of the American College of Physicians, when the guideline was released.
Also read: What your body actually goes through in the weeks after you stop drinking
The access problem, and the app that changed it
The main reason people still get a pill instead is availability. The Journal of General Internal Medicine review identified just 752 CBT-I specialists worldwide, most of them in the United States, and found that fewer than 10 percent of patients with a likely insomnia diagnosis are ever referred to CBT-I. Many patients also assume, wrongly, that sleeping pills are the only option.
Digital programs are closing that gap. In March 2020 the FDA cleared Somryst, a prescription digital therapeutic originally developed by Pear Therapeutics and now offered by Nox Health, which delivers CBT-I through a smartphone or tablet. It was evaluated in two randomized controlled trials involving more than 1,400 adults with insomnia.
Anyone with persistent sleep problems should talk to a doctor about whether CBT-I, in person or through a prescription app, is a fit before settling on long-term medication.
Also read: Researchers ran a two-year walnut trial: The most harmful LDL particles fell
Also read: What happens to your heart if you eat one avocado a day?